UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

~~February~~March 268, 2021

TAURIGA SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Florida

000-53723

30-0791746

(State or other jurisdiction

of incorporation)

(Commission

File #)

(IRS Employer

Identification Number)

4 Nancy Court, Suite 4

Wappingers Falls, NY 12590(Address of principal executive office)

(Address of principal executive office)

Tel: (917) 796-9926

(Registrant’s telephone number)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		TAUG		OTCQB

Item 7 5.0102 ~~Regulation~~Departure FDof ~~Disclosure.~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~SciSparc~~Effective ~~Ltd~~March 8, 2021, Tauriga Sciences, Inc. (OTCQB stock symbol: TAUG, the “Company”) appointed each of Messrs. James Rosati and Chris Sferruzzo to serve as members of its board of directors (the “Board).

~~Tauriga~~Mr. ~~Sciences~~Rosati is a multi-disciplinary business leader with more than 25 years of Chief Executive experience in the insurance, ~~Inc~~manufacturing, telecommunications, banking and investment banking industries. ~~(OTCQB~~Jim’s ~~stock~~areas ~~symbol:~~of ~~TAUG~~functional specialty include financial management, strategic ~~the~~planning, ~~“Company”)~~corporate ~~participated~~governance and personnel development. Dating back to 1972, Jim has served in asenior positions in private ~~placement~~industry, ~~equity~~government ~~offering~~appointments byand ~~SciSparc Ltd~~community activities. ~~(“SciSparc”)~~In 2017, ~~formerly~~Jim ~~known~~retired as ~~Therapix~~the ~~Biosciences~~Chief ~~Ltd.)~~Executive ~~(OTCQB:~~Officer ~~SPRCY),~~and ~~which~~President of isBeacon Mutual Insurance Company, a ~~specialty~~prominent Rhode Island based insurance carrier, ~~clinical-stage~~after having been elevated to chief executive ~~pharmaceutical~~in ~~company~~2007 ~~focusing~~to onlead their successful turnaround through the ~~development~~implementation of ~~cannabinoid-based~~over ~~treatments.~~100 ~~Aegis~~new ~~Capital~~policies, ~~Corp~~and significantly improving both its corporate governance and cultural dynamics. ~~acted~~From as2017 ~~the~~to ~~exclusive~~present, Jim has held board memberships and/or advisory roles for ~~placement~~a ~~agent~~number of for profit and non-profit entities, and has also been an investor in ~~connection~~both ~~with~~privately held and publicly traded company, including in the ~~offering.~~pharmaceuticals ~~The~~and ~~Company~~healthcare industries. Jim was ~~solely~~also anamed ~~participant~~one inof the ~~offering~~Top ~~and~~25 ~~paid~~Business noLeaders ~~placement,~~in ~~finder~~Rhode Island orby ~~other~~the ~~fees~~Providence toBusiness News. Mr. Rosati is a veteran of the ~~placement~~United ~~agent~~States orCoast ~~others~~Guard and a graduate of Bryant University where he earned a bachelor’s degree in ~~connection~~Economics. ~~with~~Mr. ~~this~~Rosati ~~transaction~~will serve as an independent board member.

~~SciSparc’s~~Mr. ~~business~~Sferruzzo ~~model~~currently isserves ~~complementary~~as the Executive Vice President, Finance of Bozzutos Inc., a multi-billion dollar gross revenue distribution and logistics company based in Connecticut which was founded in 1945, with ~~our~~multiple ~~own~~distribution ~~ongoing~~centers ~~pharmaceutical~~that ~~development~~wholesale ~~efforts~~dry groceries, dairy and delicatessen items, ~~therefore~~meat, wepoultry, ~~will~~seafood, ~~explore~~produce, ~~the~~and ~~possibility~~non-food items to retail supermarkets, grocery stores, and ~~for~~independently-owned ~~collaboration~~convenience ~~between~~stores, ~~our~~as ~~two~~well ~~companies~~as inthe recently announced agreement to sell the ~~future~~Company’s Tauri-gum products on ~~potential~~its ~~drug~~E-Commerce Platform. Prior to joining Bozzuto’s, Mr. Sferruzzo was a senior portfolio manager at Lazard Asset Management where he oversaw a global fixed income and~~/or~~ ~~product~~equity ~~development~~derivative portfolio of 3.5 billion in assets comprising of investments from municipalities, family offices and corporate pension funds. Prior to joining Lazard, Mr. Sferruzzo served as ~~opportunities~~Chief Investment Officer at Argent Funds Group, where he oversaw the Global Fixed Income and ~~timing~~Equity Portfolio management teams. His team was recognized ~~prove~~as ~~mutually~~Best ~~feasible~~in Class in 2006 and 2007 by Institutional Investor. OfMr. ~~course~~Sferruzzo also served as Managing Director for McMahan Securities where he was responsible for growing Sales & Trading, wewhich ~~cannot~~attained ~~guarantee~~record ~~that~~performance aunder ~~collaborative~~his ~~effort~~leadership. ~~will~~Throughout ~~ultimately~~his career ~~occur~~he has acquired intense experience in P&L Ownership and Management. Mr. Sferruzzo has focused on investing in various companies leveraging his experience in corporate restructurings, ~~nor~~Mergers and Acquisitions and managing teams to strengthen innovation, marketing and operational efficiency. Mr. Sferruzzo holds a Masters of Business Administration from the ~~possibility~~University of Connecticut and a Bachelor’s of ~~any~~Science ~~such~~in ~~efforts~~Finance from Saint John’s ~~success~~University. Mr. Sferruzzo will serve as a non-independent Board member.

~~The~~As ~~Company’s~~compensation ~~investment was~~ for ~~$88,375~~Mr. ~~as part of SciSparc~~Rosati’s ~~syndicated~~Board ~~$8.15M~~services, ~~offering to accredited and institutional investors at an offering price of $7~~Mr.07 ~~per~~Rosati ~~Unit.~~has ~~Each~~been ~~Unit~~granted ~~consists of~~ 1,000,000 ~~American~~restricted ~~Depositary~~shares ~~Share~~of ~~(“ADS”),~~the ~~one (1)~~Company’s ~~Series~~common Astock. ~~Warrant~~Mr. ~~and~~Sferruzzo ~~one-half~~has ~~(½)~~been ~~Series~~granted ~~B Warrant~~1.5 ~~The~~million ~~Series~~restricted Ashares ~~Warrants~~of ~~have~~the anCompany’s ~~exercise~~common ~~price of $7.07~~stock, ~~subject~~in topart ~~adjustments~~in recognition ~~therein.~~of ~~The~~the ~~Series~~assistance Band ~~Warrants~~support ~~have~~he anhas ~~exercise~~provided ~~price equal~~ to ~~$10.60,~~the ~~subject~~Company tosince ~~adjustments therein~~2019. ~~The~~Each ~~Series~~of AMr. ~~Warrants~~Rosati’s and ~~the~~ ~~Series~~Mr. BSferruzzo’s restricted ~~Warrants~~shares ~~are~~shall ~~exercisable~~be ~~beginning~~issued ~~six~~simultaneous ~~(6)~~with ~~months from~~ the effective date of ~~issuance~~their appointment, and ~~have~~at ~~a term of exercise equal to five (5) years from~~ the ~~initial~~market ~~exercise~~closing ~~date.~~price ~~In connection with its investment, Tauriga Sciences Inc. acquired 12,500 Units,~~per ~~consisting~~share of ~~(a)~~our ~~12,500~~common ~~Shares~~stock ~~SPRCY~~on atMarch ~~a cost basis of $7.07 per share~~5, 2021 (b)the ~~12,500~~date ~~Warrants~~immediately topreceding atthe aeffective ~~strike~~date ~~price~~ of ~~$7.07~~their ~~per~~Board ~~share and (c~~appointment) ~~6,250 Warrants to at an strike price of $10~~.~~60 per share.~~

~~Aegea~~The ~~Biotechnologies~~Company’s ~~Inc~~Board believes that each of Mr. Rosati’s and Mr. Sferruzzo’s extensive executive level experience, having served on or as an advisor to other company boards, knowledge of operational, organizational and financial matters makes them highly qualified and valuable appointees to our Board.

As previously (and more fully) described in our periodic reports, including in our most recently filed Form 10-Q filed of February 22, 2021, on April 3, 2020, the Company had. entered into a collaboration agreement (“Collaboration Agreement”) with Aegea Biotechnologies Inc. (“Aegea”), as subsequently amended, in which the Company had agreed to provide financing to Aegea in connection with Aegea’s development efforts of a Covid 19 test kit, such financing to primarily come from our then existing equity line of credit facility. On January 6, 2021, however, the Company determined to terminate its equity line of credit facility and, therefore, effectively eliminate any further obligation to additional funding to Aegea under the Collaboration Agreement. On February 26, 2021, as part of a settlement agreement concluding the Collaboration Agreement, the Company acquired an additional 69,552 common shares of Aegea, increasing the Company’s total holdings to 139,104 Aegea shares (representing a 2.04% stake as of the date of the settlement date). We believe our assistance to Aegea proved valuable and hope that the respective parties’ collaborative efforts provide value to our shareholders in the future, although we cannot provide any guarantee of such success.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 58, 2021

TAURIGA SCIENCES, INC.

By:	/s/ Seth M. Shaw
	Seth M. Shaw
	Chief Executive Officer

Filing Compare · TAURIGA SCIENCES, INC.